Related Experiment Video
Updated: Oct 21, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
The impact of the American Heart Association guidelines on patients treated for incomplete Kawasaki disease
Megan M Blaney1, Richard V Williams2, Igor A Areinamo3
1Division of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Insights
Many incomplete Kawasaki disease patients did not meet American Heart Association guidelines. Consulting pediatric cardiology improved guideline adherence for Kawasaki disease treatment.
Area of Science:
- Pediatrics
- Cardiology
- Infectious Diseases
Background:
- Kawasaki disease (KD) is a leading cause of acquired pediatric heart disease.
- Incomplete KD diagnosis poses challenges in timely and appropriate management.
- American Heart Association (AHA) guidelines aim to standardize incomplete KD diagnosis and treatment.
Purpose of the Study:
- To compare the adherence to AHA guidelines for incomplete Kawasaki disease.
- To evaluate the impact of cardiology consultation on guideline adherence.
Main Methods:
- Retrospective cohort study of patients under 18 treated for KD.
- Comparison of patients treated for incomplete KD based on AHA guideline adherence.
- Analysis of demographics, clinical data, coronary artery abnormalities, and cardiology consultation.
Main Results:
- 31% of KD patients had incomplete KD; 74% followed AHA criteria.
- Coronary artery abnormalities were found in 42% of incomplete KD patients.
- AHA guideline adherence was significantly higher with cardiology consultation (76% vs. 48%).
Conclusions:
- Over 25% of incomplete KD cases did not meet AHA guidelines.
- Pediatric cardiology consultation is associated with improved adherence to incomplete KD guidelines.
- Consultation with pediatric cardiology experts is recommended for managing incomplete KD.
Objectives:
To compare patients treated for incomplete Kawasaki disease whose practitioners followed versus did not follow American Heart Association criteria and to evaluate the association of cardiology consultation with adherence to these guidelines.
Study Design:
Single centre retrospective cohort study of patients <18 years old who received ≥1 dose of intravenous immunoglobulin for Kawasaki disease between 01/2006 and 01/2018. We collected demographics, clinical and laboratory data, coronary artery abnormalities, and cardiology consultation status. Patients treated for incomplete Kawasaki disease were divided into two groups based on adherence versus nonadherence to American Heart Association guidelines and compared by Wilcoxon rank sum test and chi-squared or Fisher's exact test.
Results:
Of the 357 patients treated for Kawasaki disease, 109 (31%) were classified as incomplete Kawasaki disease. The American Heart Association algorithm for identifying patients with incomplete Kawasaki disease was followed in 81/109 (74%). Coronary artery abnormalities were present in 46/109 (42%) of the patients who were treated for incomplete Kawasaki disease. Cardiology consultation was more frequent in those fulfilling American Heart Association criteria for the diagnosis of incomplete Kawasaki disease versus those who did not fulfill criteria (76% versus 48%, p = 0.005).
Conclusions:
Over 25% of patients treated for incomplete Kawasaki disease did not meet American Heart Association guidelines. Guidelines were more frequently followed when the paediatric cardiology team was consulted. Consulting physicians with experience and expertise in the evaluation and management of incomplete KD should be strongly considered in the care of these patients.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rheumatic Heart Disease III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Atherosclerosis III: Management
Heart Failure VI: Adjunct Therapies
Coronary Artery Disease V: Interprofessional Care

